Dangers of non sedating antihistamines pubmed
The efficacy of the new nonsedating antihistamines loratadine and cetirizine was compared in a randomized, single-blind, crossover, controlled study with that of the classical antihistamines cyproheptadine and ketotifen in seven patients with primary acquired cold urticaria (ACU).The patients received each of the four drugs for 14 consecutive days with a 7-day interval between drugs.Current international guidelines need to be revised in the light of the recent evidence.Research into aspects of pharmacokinetics and efficacy and adverse effect profiles of bilastine in children under 12 years of age is needed as are dose-response assessments and studies planned rigorously with the aim of assessing quality of life effects.Therefore, it is recommended that bilastine is taken at least one hour before and no sooner than two hours after a meal.
The aim of this paper is to review the current evidence of bilastine in the treatment of allergic rhinoconjunctivitis and urticaria.
This study suggests that both loratadine and cetirizine may be effective in the treatment of primary ACU.
Bilastine is a new, well-tolerated, nonsedating H1 receptor antihistamine.
Current guidelines for diagnosis and treatment of allergic rhinoconjunctivitis and urticaria recommend nonsedating antihistamines as first line treatment [1, 2].
Though they are helpful in many patients with mild disease, the available non-sedating antihistamines may not be sufficiently efficacious in moderate to severe conditions [1, 2].